Genetics and pathogenesis of Parkinson's syndrome
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
BACKGROUND Sphingosine 1-phosphate (S1P), a product of membrane sphingolipid
metabolism, is secreted and acts through G protein–coupled S1P receptors (S1PRs) in …
metabolism, is secreted and acts through G protein–coupled S1P receptors (S1PRs) in …
GBA Variants and Parkinson Disease: Mechanisms and Treatments
L Smith, AHV Schapira - Cells, 2022 - mdpi.com
The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …
[HTML][HTML] Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic
T Logan, MJ Simon, A Rana, GM Cherf, A Srivastava… - Cell, 2021 - cell.com
GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin
(PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn …
(PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn …
The role of ceramide and sphingosine-1-phosphate in Alzheimer's disease and other neurodegenerative disorders
K Czubowicz, H Jęśko, P Wencel, WJ Lukiw… - Molecular …, 2019 - Springer
Bioactive sphingolipids—ceramide, sphingosine, and their respective 1-phosphates (C1P
and S1P)—are signaling molecules serving as intracellular second messengers. Moreover …
and S1P)—are signaling molecules serving as intracellular second messengers. Moreover …
Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disease, the main
pathological hallmark of which is the accumulation of α-synuclein (α-syn) and the formation …
pathological hallmark of which is the accumulation of α-synuclein (α-syn) and the formation …
Therapeutics in the pipeline targeting α-synuclein for Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …
The role of lipids in Parkinson's disease
H **coy, B Wieringa, GJM Martens - Cells, 2019 - mdpi.com
Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive
loss of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and …
loss of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and …
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
Heterozygous mutations in GBA, the gene encoding the lysosomal enzyme
glucosylceramidase beta/β-glucocerebrosidase, comprise the most common genetic risk …
glucosylceramidase beta/β-glucocerebrosidase, comprise the most common genetic risk …
Cellular and molecular basis of neurodegeneration in Parkinson disease
XS Zeng, WS Geng, JJ Jia, L Chen… - Frontiers in aging …, 2018 - frontiersin.org
It has been 200 years since Parkinson disease (PD) was described by Dr. Parkinson in
1817. The disease is the second most common neurodegenerative disease characterized …
1817. The disease is the second most common neurodegenerative disease characterized …